Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000628:therapy; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D001787:Blood Group Incompatibility; D001792:Blood Platelets; D001803:Blood Transfusion; D002277:Carcinoma / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007223:Infant; D007945:Leukemia, Lymphoid / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012204:Rh-Hr Blood-Group System; D013997:Time Factors; D065227:Transfusion Reaction; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy
D000906:Antibodies; D007166:Immunosuppressive Agents; D012204:Rh-Hr Blood-Group System; D005472:Fluorouracil; D011241:Prednisone